Drug intelligence / Profile preview

FDQ21A-NH

Development stage: Unknown
Lead developer: GSK
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

FDQ21A-NH is an mRNA-based monovalent influenza vaccine candidate developed by GSK. It is currently being evaluated in Phase I/II clinical trials to assess safety, reactogenicity, and immunogenicity in healthy younger and older adults. The product is a combination formulation involving the mRNA sequence GSK4382276A, designed to elicit an immune response against influenza viruses. The vaccine utilizes mRNA technology to induce the production of viral antigens within the host, stimulating both humoral and cellular immunity.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on FDQ21A-NH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FDQ21A-NH.

Explore the full profile